ALK and non-small cell lung carcinoma: The promising results from pivotal KEYNOTE-001/010/024/042 studies prompted the FDA and other regulatory agencies to approve pembrolizumab as the first- and second-line treatment in patients with NSCLC without EGFR or ALK alterations but had positive PD-L1 tissue expression20,26–30.